Skip to main content

Want a detailed portfolio tracker?

Performance analysis of ARS Pharmaceuticals (SPRY)

Annual Return

Over the past 3 years, SPRY has had an average annual return of +7.14%, underperforming the benchmark SPY, which returned +22.77% annual.

Over the past 5 years, SPRY has had an average annual return of -20.99%, underperforming the benchmark SPY, which returned +14.05% annual.

Since Dec 4, 2020, SPRY has had an average annual return of -17.13%, underperforming the benchmark SPY, which returned +15.58% annual.

2026202520242023202220212020
-23.61%+10.43%+92.52%-35.76%+28.08%-85.63%+85.36%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-14.25%-7.11%-13.47%+2.86%+9.81%-1.87%-23.61%
2025+23.41%-19.51%+20.04%+11.05%+3.29%+20.93%+1.32%-34.28%-13.51%-10.85%+6.47%+22.12%+10.43%
2024+13.32%+34.78%+22.10%-14.87%+2.07%-4.17%+27.73%+19.41%+11.71%+1.52%-1.43%-27.29%+92.52%
2023-19.58%+30.03%-27.02%-0.15%+7.08%-3.74%+9.70%-3.54%-46.69%-5.56%+35.29%+13.46%-35.76%
2022-26.88%-11.70%-18.37%-11.40%+12.22%+21.49%+21.70%+5.43%-2.94%+17.80%+0%+37.14%+28.08%
2021-5.22%+9.43%-9.22%-26.54%-14.10%+12.20%-1.97%-27.34%-54.64%-13.53%-18.54%-5.26%-85.63%
2020+85.36%+85.36%

Drawdown analysis of ARS Pharmaceuticals (SPRY)

The maximum drawdown for the SPRY was -95.20%, occurring on May 11, 2022. This drawdown has not yet recovered.

The current SPRY drawdown is -85.27%.

Since Dec 4, 2020 SPRY has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 4 times
DepthStartTo BottomBottomTo RecoverEndTotal
-95.20%Mar 17, 2021291May 11, 2022OngoingOngoingOngoing
-18.82%Dec 31, 20203Jan 6, 20214Jan 12, 20217
-16.61%Mar 2, 20213Mar 5, 20215Mar 12, 20218
-14.85%Jan 14, 202115Feb 5, 20217Feb 17, 202122
-8.62%Feb 17, 20214Feb 23, 20214Mar 1, 20218
-5.02%Dec 10, 20203Dec 15, 20201Dec 16, 20204
-4.41%Mar 12, 20211Mar 15, 20211Mar 16, 20212
-2.42%Dec 17, 20202Dec 21, 20202Dec 23, 20204